MedTrace Logo

Correlation Between Serum TK1 and Pathological Remission of Breast Cancer With Neoadjuvant Chemotherapy

NCT06509555 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-07-19

No results posted yet for this study

Summary

The levels and changes of sTK1 among different outcome groups in BCs with different molecular types were compared by stratification to explore whether sTK1 can be used as one of the tumor markers to predict pathological remission of NACT in BC patients.The changes of serum sTK1 level and ADC before surgery were continuously monitored, and combined with other clinicopathological factors, the pathological remission prediction model of NACT in BC patients was constructed and verified.

Conditions

  • Breast Neoplasms
  • TK1

Interventions

OTHER

non-intervention

non-intervention

Sponsors & Collaborators

  • Yunnan Cancer Hospital

    lead OTHER

Principal Investigators

  • Qi Tang, doctor · Yunnan Cancer Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2026-02-28
Completion
2026-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06509555 on ClinicalTrials.gov